RBC Capital analyst Gregory Renza raised the firm’s price target on Verastem (VSTM) to $16 from $14 and keeps an Outperform rating on the shares. The approval of Avmapki Fakzynja Co-Pack has transformed Verastem into a commercial-stage company with the first FDA-approved drug in LGSOC, low-grade serous ovarian cancer, and the launch blueprint with key strategic imperatives and a pricing model are well-thought-out and supported by reasonable analogs, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue